Supernus Pharmaceuticals
SUPNIndivior is a global pharmaceutical company specializing in the development and commercialization of medicines for substance use disorders and other serious mental illnesses.
Earnings
Next report
Date not yet announcedValuation & ratios
Segments
Competitors
By market cap
By revenue growth
By net margin
Profile
Indivior is a global pharmaceutical company specializing in the development and commercialization of medicines for substance use disorders and other serious mental illnesses. The company focuses on addressing the opioid crisis through innovative long-acting injectable and transmucosal drug delivery technologies. Its value proposition is centered on providing treatment solutions that mitigate the risks of misuse and diversion while improving patient adherence.
A leading provider of buprenorphine-based treatments for opioid use disorder with a strong patent portfolio and specialized regulatory expertise in controlled substances.
FAQ
- What is Supernus Pharmaceuticals's market cap?
- Supernus Pharmaceuticals (SUPN) has a market capitalization of $1.6B and trades on NASDAQ.
- What is Supernus Pharmaceuticals's revenue and profitability?
- Supernus Pharmaceuticals generated $1.4B in trailing twelve-month revenue with net income of $450.0M, representing a net margin of 32.8%. Gross margin stands at 85.0%, with free cash flow of $31.0M. The latest reported period is Q3 2026.
- Who are Supernus Pharmaceuticals's competitors?
- Supernus Pharmaceuticals's key competitors include Alkermes, Rapport Therapeutics, Inc. Common Stock, Serina Therapeutics, Inc., and others. These companies compete in similar markets and product categories.
- What subsidiaries does Supernus Pharmaceuticals have?
- Supernus Pharmaceuticals's subsidiaries include Indivior U.K. Limited.
- Where is Supernus Pharmaceuticals headquartered?
- Supernus Pharmaceuticals is headquartered in United States of America and employs approximately 778 people. It has been publicly traded since 2012.
